rVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors

British Journal of Haematology

Volumn 92, Issue 4, 1996, Pages 1002-1004

  Smith, O P ^a,b   Hann, I M ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

haemophilia A; immune tolerance therapy; inhibitor development; IVS mutation; recombinant activated FVII

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ARTICLE; BLEEDING; CASE REPORT; CATHETER; CHILD; GENE MUTATION; HEMOPHILIA A; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029965766     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.435968.x     Document Type: Article

References (11)

1. Bell, B.A., Birch, K. & Glazer, S. (1993) Experience with recombinant factor VHa in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement: a case report. American Journal of Pediatric Hematology/Oncology, 15, 77-79.
2. Berthier, A., Pommereuil, M., Coatmelec, B., Gueret, P., Bara, L., Fauchet, R. & Samama, M.M. (1995) Direct measurement and kinetic study of activated FVII in haemophiliacs after FVIIa infusion. Thrombosis and Haemostasis, 73, 1187 (abstract 1103).
3. Hagen, F.S., Gray, C.L., O'Hara, P., Grant, F.J., Saari, G.C., Woodbury, R.G., Hart, C.E., Insley, M., Kisiel, W., Kurachi, K. & Davie, E.W. (1986) Characterization of a cDNA coding for human factor VII. Proceedings of the National Academy of Sciences of the United States of America, 83, 2413-2419.
4. Hender, U., Ljungberg, J. & Lund-Hansen, T. (1990) Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model. Blood Coagulation and Fibrinolysis, 1, 145-152.
5. Hedner, U., Schulman, S., Alberts, K.A., Blomback, M., Johnsson, H. & Glaser, S. (1988) Successful use of rFVIIa in a patient with severe haemophilia A subjected to synovectomy. Lancet, ii, 1193.
6. Hoyer, L.W. (1995) Why do so many haemophilia A patients develop an inhibitor? British Journal of Haematology, 90, 498-501.
7. Lakich, D., Kazazian, H.H., Jr. Antonarakis, S.E. & Gitschier, J. (1993) Inversions disrupting the factor VIII gene are a common cause of haemophilia A. Nature Genetics, 5, 236-241.
8. Schmidt, M.L., Smith, H.E., Gamerman, S., Di Michele, D.M., Glazer, S. & Scott, J.P. (1991) Prolonged recombinant activated factor VII (rVIIa) therapy for severe bleeding in a factor-IX-deficient patient with an inhibitor. British Journal of Haematology, 78, 460-463.
9. Stein, J. & Ratnoff, O.D. (1993) An inhibitor of antihemophilic factor (factor VIII) in an 18-month-old nonhemophilic child. American Journal of Pediatric Hematology/Oncology, 15, 346-350.
10. Tengborn, L., Kjellman, B., Elfstrand, P.O. & Bagenholm, T. (1992) Recombinant factor VIIa in an infant with haemophilia A and inhibitors. Acta Paediatrica, 81, 566-567.
11. Thim, L., Bjoern, S., Christensen, M., Nicolaisen, E.M., Lund-Hansen, T., Pedersen, A.H. & Hedner, U. (1988) Amino acid sequence and posttranstational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry, 27, 7785-7793.